This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Other endocrine disorders
  • /
  • Effect of cabergoline monotherapy in Cushing's dis...

Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis.

Read time: 1 mins
Published:1st Dec 2018
Author: Palui R, Sahoo J, Kamalanathan S, Kar SS, Selvarajan S, Durgia H.
Availability: Pay for access, or by subscription
Ref.:J Endocrinol Invest. 2018;41(12):1445-1455.
Effect of cabergoline monotherapy in Cushing's disease: an individual participant data meta-analysis

The primary treatment of choice for Cushing’s disease (CD) is the removal of the pituitary adenoma by transsphenoidal surgery (TSS). The surgical failure is seen in up to 75% of cases depending on the experience of the surgeon in different studies. Medical therapy is one of the options for the treatment of recurrent or persistent CD.

Methodology: The primary outcome of this meta-analysis was to find the proportion of patients achieving normalisation of 24-h urinary free cortisol (remission of CD) following cabergoline monotherapy. Literature search was conducted in January 2018 in PubMed/MEDLINE database from its date of inception to 31st December 2017. The search strategy used was “[(cushing) OR Cushing’s] AND cabergoline”. Individual participant data were extracted from the included studies and risk of bias was analysed by review checklist proposed by MOOSE.

Results: The individual participant data of 124 patients from six observational studies were included in this meta-analysis. 92 patients (74.2%) had past pituitary surgery. The proportion of patients achieving remission of CD with cabergoline monotherapy was 39.4% (95% confidence interval 0.31–0.49; P = 0.026). The previous surgery [odds ratio (OR) 28.4], duration of cabergoline monotherapy (OR 1.31) and maximum cabergoline dose (OR 0.19) were predictors for remission of CD. Mild and severe side effects were reported in 37.3% and 5.6% of patients, respectively, during cabergoline monotherapy.

Conclusions: This meta-analysis shows that cabergoline monotherapy is a reasonable alternative for subjects with persistent or recurrent CD after TSS. It can also be used in CD patients either as a bridge therapy while waiting for surgery or in those unwilling for surgery or have contraindication to it.


Read abstract on library site

Access full article